ArticleScientific reports2026
Montelukast attenuates diclofenac sodium-induced cardiotoxicity in male rats via targeting Wnt/β-catenin pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chasing the FoxO in Metabolic Disorders: Novel Considerations for Oxidative Stress, Programmed Cell Death, Wnt, and the Gut Microbiome.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diclofenac sodium (DCFN) is the most often prescribed NSAID, however its prolonged administration is linked to cardiotoxicity mediated by oxidative stress, inflammation, and apoptosis. The role of the Wnt/β-catenin pathway in cardiac injury is well documented; however, it remains unclear whether this pathway is upregulated in the heart during DCFN treatment. This work aims to investigate the cardiac activity of this pathway in DCFN-intoxicated rats and to explore the potential cardioprotective effects of montelukast (MNTL), a leukotriene receptor antagonist. Four groups of male rats were treated as follows for 14 days: control, MNTL control (20 mg/kg, p.o), DCFN (10 mg/kg, i.m), and DCFN+MNTL. Cardiac injury was assessed by serum biomarkers (cardiac troponin-I, creatine kinase-MB, lactate dehydrogenase, and aspartate aminotransferase), oxidative stress markers (malondialdehyde, glutathione, superoxide dismutase), pro-inflammatory cytokines (tumor necrosis factor-α, interleukin-6), as well as apoptotic proteins (Bcl-2 and caspase-3). Protein expression of Wnt-1, active β-catenin, and Frizzled-1 (FZD1) was evaluated, and histological analysis of cardiac tissues was performed. DCFN treatment resulted in significant cardiac injury, characterized by elevated serum cardiac biomarkers, increased oxidative stress and inflammatory cytokines, upregulated apoptotic markers, and overexpression of Wnt-1/active β-catenin and FZD-1. Histological examination revealed myocardial degeneration, vascular compression, and marked inflammatory cell infiltration. Co-treatment with MNTL significantly mitigated these biochemical, molecular, and histopathological alterations. In conclusion, the Wnt/β-catenin pathway is activated in the heart during DCFN treatment, suggesting its possible role in its cardiotoxicity. MNTL effectively attenuates this toxicity, highlighting its potential as a cardioprotective agent during NSAID therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.